spacer
home > ebr > winter 2002 > novel antibiotics to counteract the global threat of superbugs
PUBLICATIONS
European Biopharmaceutical Review

Novel Antibiotics to Counteract the Global Threat of Superbugs

The introduction of antibiotics in the 1950s and 1960s revolutionised medicine, to such an extent that in 1969 the US Surgeon General famously declared: "The time has come to close the book on infectious disease". Following this initial optimism, many companies left the field. While industry dollars were spent elsewhere, bacteria became resistant to antibiotics at a rapid pace. Despite renewed efforts in antibiotic discovery, resistance is now a global threat to public health.Changing population demographics, increasing use of invasive procedures, the spread of HIV, an increasing number of immunocompromised patients and misuse of broad spectrum antibiotics have meant that new pathogens have emerged, some of which are resistant to one or several of the antibiotics normally used to treat them (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne Gill, Head of Microbiology at PanTherix Ltd Anne Gill obtained her PhD in Medical Microbiology from the University of Edinburgh, specialising in the mechanisms of antibiotic action and resistance. After conducting post-doctoral research, Anne joined PanTherix, where she now holds the post of Head of Microbiology.
PanTherix is an anti-infectives company using structure-guided drug design to discover and develop antibiotics acting on novel targets.

spacer
Anne Gill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Dynascan Discusses Company Advancements With Packaging Today Magazine

Dynascan’s Marketing Manager (MM) recently met up with Europe’s leading packaging magazine, Packaging Today. During the interview many topics were covered, and you can read the full article here, but below are a few highlights and brief summary of what was discussed…
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement